D
DeWitt S. Goodman
Researcher at Columbia University
Publications - 180
Citations - 16084
DeWitt S. Goodman is an academic researcher from Columbia University. The author has contributed to research in topics: Retinol & Retinol binding protein. The author has an hindex of 70, co-authored 180 publications receiving 15820 citations. Previous affiliations of DeWitt S. Goodman include Albert Einstein College of Medicine & Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
On determining the extent of side-pool synthesis in a three-pool model for whole body cholesterol kinetics
TL;DR: Whole body cholesterol turnover is well described by a three-pool model, which has eight unknown parameters: three masses, three synthesis rates, and two intercompartmental exchange rates.
Journal ArticleDOI
Cholesteryl ester turnover in human plasma lipoproteins during cholestyramine and clofibrate therapy
TL;DR: The results suggest that neither drug has a strongly selective effect on the turnover of one particular cholesteryl ester, or in each of the three classes of plasmalipoproteins in one particular plasma lipoprotein.
Journal ArticleDOI
Stereochemistry at the center of squalene during its biosynthesis from farnesyl pyrophosphate and subsequent conversion to cholesterol.
TL;DR: Determination of the stereochemistry and distribution of the tritium label in cholesterol confirmed the fact that the hydride ion transfer is a stereospecific reaction, and allowed assignment of the absolute configuration of the asymmetrical carbon atom formed by introduction of the triphosphopyridine label.
Book ChapterDOI
Genetic Studies on a Human Plasma Transthyretin (Prealbumin) Variant Associated with Familial Amyloidotic Polyneuropathy
TL;DR: Analysis of FAP patients with familial amyloidotic polyneuropathy who are carriers of an abnormal transthyretin- TTR indicated that TTR appears to constitute a direct and true genetic marker of the disease.
Journal ArticleDOI
Influence of chlorpropamide upon postpancreatectomy and spontaneous diabetes
TL;DR: Despite the current uncertainty regarding the mechanism of the hypoglycemic effect of the aryl sulfonylureas, the observation of their failure to lower the blood sugar in severe alloxan diabetes in animals' and in depancreatized animals remains unchallenged.